Friberg Gregory R 4

What Happened

• Gregory R. Friberg, EVP & Chief R&D Officer of BioMarin Pharmaceutical (BMRN), received equity awards on March 16, 2026: 19,150 restricted stock units (RSUs) and a derivative option grant covering 45,600 shares. RSUs show $0.00 price because they are awards.
• On March 17, 2026, 1,629 shares were disposed (tax withholding) at $56.05 per share, totaling approximately $91,305 to satisfy tax obligations related to the awards. The filings use transaction codes A (award/grant) and F (tax withholding).

Key Details

• Transaction dates: grants dated 2026-03-16; tax withholding/settlement dated 2026-03-17; Form 4 filed 2026-03-18 (filed timely).
• Prices/values: RSUs and option grant listed at $0.00 (awards); 1,629 shares withheld at $56.05 = ~$91,305.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — restricted stock units granted March 16, 2026 (price not applicable). F2 — option grant vests 12/48th on March 16, 2027 and 1/48th monthly thereafter.
• Nature of transactions: RSU award and option grant are acquisitions (future/equity compensation); the share disposal was routine tax withholding, not an open-market sale.

Context

• This is primarily a compensation grant (awards and an option grant) rather than an outright purchase or investment by the insider. The withheld shares represent a standard tax-withholding event upon vesting/settlement of equity awards and do not necessarily indicate a change in the insider's market view.
• The option grant is a derivative award with a multi-year vesting schedule; those shares are not owned outright until they vest and any exercise conditions are met.